pioglitazone has been researched along with Diabetic Cardiomyopathies in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This work investigated the protective effect of pioglitazone on myocardial infarction (MI) in non-diabetic and diabetic rats, focusing on its role on advanced glycated endproducts (AGEs) and cardiac apoptotic machinery." | 7.83 | Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. ( Farag, NE; Khodeer, DM; Moustafa, YM; Zaitone, SA, 2016) |
| "All patients had a history of type 2 diabetes mellitus (T2DM) and were divided based on whether they received pioglitazone before ablation or not." | 6.76 | Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. ( Gu, J; Jiang, W; Liu, X; Shi, H; Tan, H; Wang, X; Wang, Y; Zhou, L, 2011) |
| " This work investigated the protective effect of pioglitazone on myocardial infarction (MI) in non-diabetic and diabetic rats, focusing on its role on advanced glycated endproducts (AGEs) and cardiac apoptotic machinery." | 3.83 | Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. ( Farag, NE; Khodeer, DM; Moustafa, YM; Zaitone, SA, 2016) |
| "All patients had a history of type 2 diabetes mellitus (T2DM) and were divided based on whether they received pioglitazone before ablation or not." | 2.76 | Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. ( Gu, J; Jiang, W; Liu, X; Shi, H; Tan, H; Wang, X; Wang, Y; Zhou, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Gbr, AA | 1 |
| Abdel Baky, NA | 1 |
| Mohamed, EA | 1 |
| Zaky, HS | 1 |
| Wassef, MAE | 1 |
| Tork, OM | 1 |
| Rashed, LA | 1 |
| Ibrahim, W | 1 |
| Morsi, H | 1 |
| Rabie, DMM | 1 |
| Al-Assi, O | 1 |
| Ghali, R | 1 |
| Mroueh, A | 1 |
| Kaplan, A | 1 |
| Mougharbil, N | 1 |
| Eid, AH | 1 |
| Zouein, FA | 1 |
| El-Yazbi, AF | 1 |
| Chen, WJ | 1 |
| Greulich, S | 1 |
| van der Meer, RW | 1 |
| Rijzewijk, LJ | 1 |
| Lamb, HJ | 1 |
| de Roos, A | 1 |
| Smit, JW | 1 |
| Romijn, JA | 1 |
| Ruige, JB | 1 |
| Lammertsma, AA | 1 |
| Lubberink, M | 1 |
| Diamant, M | 1 |
| Ouwens, DM | 1 |
| Yuan, M | 1 |
| Qiu, M | 1 |
| Cui, J | 1 |
| Zhang, X | 1 |
| Zhang, P | 1 |
| Breunig, IM | 1 |
| Shaya, FT | 1 |
| McPherson, ML | 1 |
| Snitker, S | 1 |
| DeFronzo, RA | 1 |
| Chilton, R | 1 |
| Norton, L | 1 |
| Clarke, G | 1 |
| Ryder, RE | 1 |
| Abdul-Ghani, M | 1 |
| Khodeer, DM | 1 |
| Zaitone, SA | 1 |
| Farag, NE | 1 |
| Moustafa, YM | 1 |
| Joubert, M | 1 |
| Jagu, B | 1 |
| Montaigne, D | 1 |
| Marechal, X | 1 |
| Tesse, A | 1 |
| Ayer, A | 1 |
| Dollet, L | 1 |
| Le May, C | 1 |
| Toumaniantz, G | 1 |
| Manrique, A | 1 |
| Charpentier, F | 1 |
| Staels, B | 1 |
| Magré, J | 1 |
| Cariou, B | 1 |
| Prieur, X | 1 |
| Gu, J | 2 |
| Liu, X | 1 |
| Wang, X | 1 |
| Shi, H | 1 |
| Tan, H | 1 |
| Zhou, L | 1 |
| Jiang, W | 1 |
| Wang, Y | 1 |
| Li, JD | 1 |
1 review available for pioglitazone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
Topics: Animals; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat | 2016 |
2 trials available for pioglitazone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes.
Topics: Activins; Adipose Tissue; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyop | 2013 |
Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; | 2011 |
8 other studies available for pioglitazone and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Cardioprotective effect of pioglitazone and curcumin against diabetic cardiomyopathy in type 1 diabetes mellitus: impact on CaMKII/NF-κB/TGF-β1 and PPAR-γ signaling pathway.
Topics: Animals; Blood Glucose; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiotonic Agents; Curc | 2021 |
Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR-γ Agonist or Exendin-4.
Topics: Animals; Cardiolipins; Diabetic Cardiomyopathies; Disease Models, Animal; Exenatide; Hypoglycemic Ag | 2018 |
Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs.
Topics: Animals; Diabetic Cardiomyopathies; Diabetic Neuropathies; Dietary Fats; Energy Intake; Glucose Into | 2018 |
Protective effects of pioglitazone against immunoglobulin deposition on heart of streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Fibrosis; Fluorescent Antibody | 2014 |
Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Topics: Adolescent; Adult; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Fee-for-Service Plans; Fema | 2014 |
Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiotonic Agents; Diabetes Mellitus, Type 2; Diabeti | 2016 |
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type | 2017 |
Testing each hypothesis marginally at alpha while still controlling FWER: how and when.
Topics: Biostatistics; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Human | 2013 |